Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
about
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesPhase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.CDK inhibitors in clinical development for the treatment of cancer.A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.Small-molecule cyclin-dependent kinase modulators.Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaOn the evolution of statistical methods as applied to clinical trials.Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.Clinical anticancer drug development: targeting the cyclin-dependent kinases.Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells.Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phaseRecent progress in the discovery and development of cyclin-dependent kinase inhibitors.Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicityA dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.Small molecule signal transduction inhibitors for the treatment of solid tumors.Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.Selective antitumor activity of roscovitine in head and neck cancer.Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in miceThe CDK inhibitors in cancer research and therapy.Novel targeted therapies in head and neck cancer.Dinaciclib for the treatment of breast cancer.Recent trends in preclinical drug-drug interaction studies of flavonoids--Review of case studies, issues and perspectives.Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.A novel liposomal formulation of flavopiridol.A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model.Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target.Targeting cell cycle kinases and kinesins in anticancer drug development.
P2860
Q21245492-C2110CE8-2DA3-4E0C-8FDA-805D363480C9Q33417803-F867ECA1-F9B3-4590-ABE1-D83D7FE293B7Q33952759-A3DFEE92-E279-4F67-BE3D-E990483488CBQ34754350-4622DFEA-806B-465F-8E97-FEE18EE85E97Q35143997-39D27388-6B0D-4CA6-99B1-45061CA2A243Q35220471-A6EC3CB5-BC11-4E6F-B7A1-5FEA2183E3FFQ35551149-C512D194-BCCE-45F1-A4B3-20C7E96D7B77Q35615823-C21CF38D-13AB-4A04-9EDC-575FE4815A64Q35743841-C96C75BD-5386-47C0-B84E-F7E5DB0AD168Q35848241-949AA3EF-B474-49D0-8220-6A4B7B319B93Q35959477-31E1E43D-34D4-48E9-9691-04EC3D0B6E2EQ36002265-70CB7467-05F8-4D00-BD02-1B760A27B688Q36002546-69D6706C-4CD1-414C-8E16-8FD367444DCFQ36017262-3746DF5F-3033-40A4-BF41-B4AAF2A956D7Q36120794-B779CA3D-7514-42C3-BF44-21D937A586AAQ36247797-87B33531-2B2D-426B-81D2-7D500A715DD7Q36363971-E1071B86-CB2B-465D-8EDB-D87CE3271187Q36366636-AC54829A-67B5-408B-8528-1622CEFC407CQ36745599-E69C6405-CD13-4C65-B9D4-5E4C13BEEC75Q36776441-F9462813-6741-46FB-BB18-82B89CF19CC5Q36825077-1CE2CD72-9AE9-4DBE-9BB4-9AF69A1FE745Q36895413-0A9FE8D1-96C0-4176-936D-9F45904540CFQ37163806-8D977E72-FEC3-42BA-B709-1317847C2862Q37424813-230DF7F7-F99A-4E68-B4A2-30484FC15364Q37437594-0CB5FF0C-17BC-4628-9F34-C5D8297FDB58Q37585018-240AC0D8-232A-4BE1-803B-FF2DEB2B5946Q37923861-21488D49-1707-4985-8AD0-9337457D9E2FQ37975224-2DA1FFE3-8595-478E-A05D-B2F8814F2206Q38238282-8E0C92AD-B99D-4610-AD54-F3C730475078Q38581733-2634800A-5291-4D9B-B8B8-06007F5499D0Q38973410-197DED13-4783-4DBC-97DD-33FF6F578963Q39696728-90E0BF70-2563-4F23-AD4E-B92A0161914FQ41900653-2D593246-2C12-4A05-909F-9724E09755F8Q41993498-6F6FAADC-9AAE-43D8-851F-975D2F02D706Q44602400-F964DC5F-F687-49CD-AF64-094BCB3F86E7Q45240536-FEB8F999-5722-4FF0-894A-571BA2E9CE37Q47836904-D773E054-EBD7-458C-99C8-825388BDFF1DQ52639097-F9194E32-B79A-460A-AF69-EAB3D2856983
P2860
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Phase I clinical and pharmacok ...... ients with advanced neoplasms.
@en
type
label
Phase I clinical and pharmacok ...... ients with advanced neoplasms.
@en
prefLabel
Phase I clinical and pharmacok ...... ients with advanced neoplasms.
@en
P2093
P356
P1476
Phase I clinical and pharmacok ...... ients with advanced neoplasms.
@en
P2093
Adrian M Senderowicz
Anthony J Murgo
Antoinette R Tan
Donna Headlee
Edward A Sausville
Giovanni Melillo
Richard Messmann
Suoping Zhai
Susan G Arbuck
William D Figg
P304
P356
10.1200/JCO.2002.01.043
P407
P577
2002-10-01T00:00:00Z